<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565483</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0292</org_study_id>
    <nct_id>NCT04565483</nct_id>
  </id_info>
  <brief_title>Predictive Signature of Benralizumab Response</brief_title>
  <acronym>BENRAPRED</acronym>
  <official_title>Predictive Signature of Benralizumab Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministère de la Santé - France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to establish the predictive value of early blood gene&#xD;
      expression signature of Benralizumab response associated with a significant reduction of the&#xD;
      number of exacerbations in treated severe asthmatic patients.&#xD;
&#xD;
      This trial is a French, multicenter and no-randomized trial. Patients enrolled will be&#xD;
      clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6&#xD;
      clinical visit on site and in phone call at 13 months)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive value of early blood gene expression signature of Benralizumab</measure>
    <time_frame>12 months</time_frame>
    <description>To establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. We will evaluate an early blood gene expression signature of Benralizumab response through a clinically relevant reduction of the number of exacerbations at month 12 (M12).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular signature predictive of stabilization</measure>
    <time_frame>12 months</time_frame>
    <description>To establish at M0 (baseline) a molecular signature predictive of stabilization in severe asthmatic patients treated by Benralizumab. At M0 a composite blood molecular signature predictive of reduction of the exacerbation rate at M12 in severe asthmatic patients treated by Benralizumab will be assessed. The definition of stable class of patients (low category) is used as a target for the prediction. The methods used for the primary objective are applied to secondary objective using similar input data on a different 3-class prediction target.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The stability of the signature over time</measure>
    <time_frame>0 month, 3 months, 6 months and 9 months</time_frame>
    <description>To evaluate the stability of the signature over time (from early at M0, M3, to late prediction at M6 and M9) considering patient trajectories. The significance of center and the relevance of time dependent modelling will be evaluated using generalised mixed models on independently established molecular response signature. It is expected a robust and reproducible gene expression to assess the inter and intra-individual trajectories of the signature over time and across centers (from early at M0 and M3, to late prediction at M6 and M9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association of gene expression patterns</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the association of gene expression patterns with both objective and subjective improvement. Correlations network between blood gene expression of Benralizumab significant response will be assessed thanks to weighted gene correlation network analysis (gene co-expression network analysis (WGCNA)) with an expected increase in forced expiratory volume at one second (FEV1) + Asthma Quality of Life Questionnaire (AQLQ) + peak-flow values and expected decrease of Asthma Control Questionnaire-7 items (ACQ-7), -6 items (ACQ-6) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of gene expression patterns and clinical characteristics</measure>
    <time_frame>0 months</time_frame>
    <description>To evaluate association of gene expression patterns at M0 (baseline) and clinical characteristics of frequent exacerbations. Correlations network between blood gene expression at M0 and clinical characteristics of frequent exacerbations will be assessed thanks to WGCNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stratification value of gene expression in severe asthma</measure>
    <time_frame>12 months</time_frame>
    <description>To assess the stratification value of gene expression in severe asthma and its correlation with clinical subgroups and clinically meaningful variables such as number of exacerbations. Correlation network between stratification value of gene expressions in severe asthma and its correlation with clinical subgroups will be assessed thanks to WGCNA. This analysis is based on pairwise correlations between genetic variables and clinical variables underlying the amount of overall variance captured by high dimensional gene expression datasets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scenario-based cost-utility analysis</measure>
    <time_frame>12 months</time_frame>
    <description>To conduct a scenario-based cost-utility analysis.Concerning cost-utility analysis, two strategies of treatment with Benralizumab will be compared: the first one will consider a strategy not using an early blood gene expression signature of Benralizumab response and the second will consider a simulated strategy using an early blood gene expression signature of Benralizumab response.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Asthma; Eosinophilic</condition>
  <condition>Severe Asthma</condition>
  <arm_group>
    <arm_group_label>BENRALIZUMAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion after a one-month screening period. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benralizumab Prefilled Syringe</intervention_name>
    <description>Patients receive BENRALIZUMAB if they meet the criteria for inclusion and non-inclusion after a one-month screening period. Injections take place at the inclusion visit, at 1 month, 2 months, 4 months, 6 months, 8 months, 10 months and 12 months.</description>
    <arm_group_label>BENRALIZUMAB</arm_group_label>
    <other_name>Transcriptomic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients between 18 and 75 years old.&#xD;
&#xD;
          -  Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.:&#xD;
&#xD;
               -  asthma requiring high doses of ICS (&gt;1000 microgram per day of Beclomethasone or&#xD;
                  equivalent) associated with LABA and/or systemic corticosteroids to be controlled&#xD;
                  over one year,&#xD;
&#xD;
               -  and/or uncontrolled asthma despite the later medications,&#xD;
&#xD;
               -  and/or a controlled asthma worsening after decreasing medications,&#xD;
&#xD;
          -  Pre-BronchoDilatator (BD) FEV1 &lt;80% of the predicted value at M-1.&#xD;
&#xD;
          -  Documented historical reversibility of FEV1 ≥12% and FEV1 gain ≥ 200 milliliter&#xD;
&#xD;
          -  ACQ-7 score ≥ 1,5 at M-1 and M0.&#xD;
&#xD;
          -  ≥ 3 exacerbations in the 12 months prior to screening visit M-1.&#xD;
&#xD;
          -  Eosinophil blood count ≥ 0,3 G/L at screening visit or in the 12 months prior to the&#xD;
             screening visit. If eosinophil blood count is ≥ 0,15 G/L and &lt; 0,3 G/L, an&#xD;
             eosinophilic phenotype defined by at least 1 of the following criteria will be&#xD;
             required:&#xD;
&#xD;
               -  Fractional Exhaled Nitric Oxide (FeNO) &gt; 25 ppm at screening visit or in the 12&#xD;
                  months prior to the screening visit.&#xD;
&#xD;
               -  Sputum eosinophils ≥ 3% at screening visit or in the 12 months prior to the&#xD;
                  screening visit.&#xD;
&#xD;
          -  Patients who provide written informed consent prior to participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with difficult-to-treat asthma and/or with uncontrolled asthma&#xD;
             differential diagnosis according to the judgment of the investigator (e.g., vocal cord&#xD;
             dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis,&#xD;
             obstructive sleep apnea syndrome, hyperventilation syndrome, allergic&#xD;
             broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma/COPD overlap&#xD;
             syndrome).&#xD;
&#xD;
          -  Non-adherent patients to inhaled treatment (ICS + LABA).&#xD;
&#xD;
          -  Active smokers or former smokers exceeding 20 packs year.&#xD;
&#xD;
          -  Exacerbation at screening visit M-1.&#xD;
&#xD;
          -  Exacerbation within the past 4 weeks prior to M0, to avoid confounding effects of a&#xD;
             short course of systemic corticosteroids that could bias basal molecular signature.&#xD;
&#xD;
          -  Active malignancy or malignancy in remission over less than 5 years.&#xD;
&#xD;
          -  Active parasitic infection or parasitic infection in the past 24 weeks.&#xD;
&#xD;
          -  Hypersensitivity to Benralizumab or to any of the excipients of Fasenra® (histidine,&#xD;
             histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20)&#xD;
&#xD;
          -  Patients requiring other immunosuppressive and immunomodulator drugs&#xD;
&#xD;
          -  Patients requiring other biotherapy than Benralizumab, with or without French's&#xD;
             marketing authorisation in severe asthma&#xD;
&#xD;
          -  Patients requiring other biotherapy than Benralizumab that affects the immune system&#xD;
&#xD;
          -  SARS-COV2 infection&#xD;
&#xD;
          -  Pregnancy, lactation, or patients with childbearing potential refusing efficient&#xD;
             contraceptive method.&#xD;
&#xD;
          -  Patients under psychiatric condition altering their comprehension and their ability to&#xD;
             give informed consent.&#xD;
&#xD;
          -  Patients already enrolled in a clinical interventional research.&#xD;
&#xD;
          -  Patients not affiliated to a health insurance plan&#xD;
&#xD;
          -  Patients under guardianship, curators or safeguard of justice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>François-Xavier BLANC, MD-PHD</last_name>
    <phone>+33240165545</phone>
    <email>xavier.blanc@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hakima OUKSEL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Olivier GIRODET, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe BONNIAUD, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PISON, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre - AP-HP</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc HUMBERT, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François GOUPIL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie FRY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles DEVOUASSOUX, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal CHANEZ, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud BOURDIN, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François-Xavier BLANC, MD-PHD</last_name>
      <phone>+33240165545</phone>
      <email>xavier.blanc@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat - AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille TAILLE, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume MAHAY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naji KHAYATH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital FOCH</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine MAGNAN, MD-PHD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain DIDIER, PD-PHD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>therapeutic monoclonal antibody</keyword>
  <keyword>personalized medicine</keyword>
  <keyword>transcriptomic</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Pulmonary Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

